Key result
Cardiac resynchronization therapy with a defibrillator (CRT-D) did not significantly reduce all-cause mortality compared to a pacemaker (CRT-P) in patients with heart failure.
Why the study?
The choice between CRT with or without a defibrillator in elderly patients remains controversial.
Does CRT-D reduce mortality compared to CRT-P in patients with heart failure, particularly the elderly?
Observational (n=285)
No
Does CRT-D reduce mortality compared to CRT-P in patients with heart failure, particularly the elderly?
In patients with heart failure undergoing CRT, the addition of a defibrillator (CRT-D) did not significantly improve survival compared to CRT-P, suggesting comorbidities should guide device selection in the elderly.
One benefit of an implantable cardioverter-defibrillator is the prevention of sudden cardiac death (SCD). It is recommended for patients with a low left ventricular ejection fraction (LVEF). However, the choice of cardiac resynchronization therapy (CRT) with or without a defibrillator (CRT-D and CRT-P) in elderly patients is controversial. To understand the current situation for proper device selection, we investigated the impact of defibrillators on mortality in elderly patients with heart failure.Consecutive patients who underwent CRT implantation were retrospectively recruited. Baseline characteristics, all-cause mortality, cardiac death, and defibrillator implantation rates were investigated in patients aged > 75 or ≤ 75 years.A total of 285 patients (79 patients aged > 75 years) were analyzed. Elderly patients had more comorbidities, but a lower proportion had ventricular arrhythmia. During the mean follow-up of 47 months, 109 patients died (67 due to cardiac death). Kaplan-Meier analysis showed higher mortality in elderly patients (P = 0.0428) but no significant difference in cardiac death by age group (P = 0.7472). There were no significant differences in mortality between patients with CRT-D versus CRT-P (P = 0.3386).SCD was rare. A defibrillator had no significant impact on mortality. In elderly patients, comorbidities are common and related to mortality. The selection of CRT-D versus CRT-P should take those factors into account.
No takes yet. Share an insight, caveat, or question.
Mano et al. (2023) conducted an observational in Heart failure (n=285). Cardiac resynchronization therapy with a defibrillator (CRT-D) vs. Cardiac resynchronization therapy with a pacemaker (CRT-P) was evaluated on All-cause mortality (p=0.3386). Cardiac resynchronization therapy with a defibrillator (CRT-D) did not significantly reduce all-cause mortality compared to a pacemaker (CRT-P) in patients with heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: